Bocsci2018

BzNH-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and benzoyl-amide, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase[1].

BSJ-03-123 is a potent, CDK6-selective small-molecule degrader (PROTAC) that uniquely enables rapid pharmacological interrogation of CDK6-dependent functions;

Boc-C5-O-C5-O-C6-Cl is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.

Boc-C1-PEG2-C4-Cl is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.

1,5-Dihydrobenzo[1,2-d:4,5-d']bis([1,2,3]triazole)

4-Aminoisochromane Hydrochloride

3-Amino-7-azaindole Dihydrochloride

imidazo[1,2-b]pyridazine-3-carbaldehyde

NH2-C5-NH-Boc is a PROTAC linker, which refers to the alkyl chain composition.

Boc-NH-PEG2-C2-NH2 is a PROTAC linker, which refers to the alkyl/ether composition. Boc-NH-PEG2-C2-NH2 can be used in the synthesis of a series of PROTACs.

NH2-PEG3-C2-NH-Boc is a PROTAC linker, which refers to the alkyl/ether composition. NH2-PEG3-C2-NH-Boc can be used in the synthesis of a series of PROTACs.

NH2-PEG5-C2-NH-Boc is a PROTAC linker, which refers to the alkyl/ether composition. NH2-PEG5-C2-NH-Boc can be used in the synthesis of a series of PROTACs.

MZP-55 is a selective degrader of BRD3/4 based on PROTAC technology, with a Kd of 8 nM for Brd4BD2. MZP-55 binds to VHL-EloC-EloB protein (VCB) with a Kd of 105 ± 24 nM.

MZP-54 is a PROTAC targeting on BET, consist of a warhead I-BET726 (BET bromodomain inhibitor) linked to a VHL ligand VH032. It exhibited affinity to the Brd4BD2

MZ 1, a hybrid compound that drives the selective proteasomal degradation of bromodomain-containing protein 4 (BRD4), retains high affinity for BRD2,

MV-1-NH-Me, the MV-1 based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER.

(Benzene-1,3,5-triyl)triacetonitrile - CAS 80935-59-7

6-Amino-2,3-dimethyl-2H-indazole Hydrochloride - CAS 635702-60-2

BOC Sciences characterizes liposome drugs according to the FDA production and control (CMC) guidelines. We can test for physicochemical properties, encapsulation efficiency, and in vitro drug release and stability, and other specifications.

BOC Sciences provides our clients with customized lipid nanometers to meet the different needs using our advanced lipid nanoparticle (LNP) technology, which represents the most widely used RNAi delivery technology to date. The LNP technology allows RNAi drugs/mRNA/small molecule drugs to be encapsulated in tiny particles made of lipids (fat or oil).